Population Pharmacokinetics of Continuous-Infusion Meropenem in Febrile Neutropenic Patients with Hematologic Malignancies: Dosing Strategies for Optimizing Empirical Treatment against Enterobacterales and
continuous-infusion meropenem
patients with hematologic malignancies
population pharmacokinetics
Journal
Pharmaceutics
ISSN: 1999-4923
Titre abrégé: Pharmaceutics
Pays: Switzerland
ID NLM: 101534003
Informations de publication
Date de publication:
19 Aug 2020
19 Aug 2020
Historique:
received:
15
07
2020
revised:
10
08
2020
accepted:
17
08
2020
entrez:
23
8
2020
pubmed:
23
8
2020
medline:
23
8
2020
Statut:
epublish
Résumé
A population pharmacokinetic analysis of continuous infusion (CI) meropenem was conducted in a prospective cohort of febrile neutropenic (FN) patients with hematologic malignancies. A non-parametric approach with Pmetrics was used for pharmacokinetic analysis and covariate evaluation. Monte Carlo simulations were performed for identifying the most appropriate dosages for empirical treatment against common Enterobacterales and
Identifiants
pubmed: 32825109
pii: pharmaceutics12090785
doi: 10.3390/pharmaceutics12090785
pmc: PMC7560225
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Antimicrob Agents Chemother. 2012 Dec;56(12):6343-8
pubmed: 23045356
Clin Ther. 2005 Nov;27(11):1820-30
pubmed: 16368453
Pharm Res. 2006 Sep;23(9):2036-49
pubmed: 16906454
PLoS One. 2018 Jun 28;13(6):e0199531
pubmed: 29953464
Antimicrob Agents Chemother. 2017 Sep 22;61(10):
pubmed: 28760900
Antimicrob Agents Chemother. 2005 Aug;49(8):3550-3
pubmed: 16048982
J Pharm Biomed Anal. 2003 Dec 4;33(5):947-54
pubmed: 14656585
J Antimicrob Chemother. 2014 May;69(5):1416-23
pubmed: 24443514
Antimicrob Agents Chemother. 1990 May;34(5):702-8
pubmed: 2360811
Ann Pharmacother. 2006 Feb;40(2):219-23
pubmed: 16449546
Expert Rev Anti Infect Ther. 2019 Dec;17(12):983-995
pubmed: 30686067
Ann Hematol. 2017 Nov;96(11):1775-1792
pubmed: 28856437
Ther Drug Monit. 2014 Oct;36(5):674-6
pubmed: 24637698
Clin Pharmacokinet. 2019 Nov;58(11):1407-1443
pubmed: 31325141
J Antimicrob Chemother. 2014 Sep;69(9):2556-62
pubmed: 24855125
PLoS One. 2012;7(12):e51612
pubmed: 23272123
Antimicrob Agents Chemother. 2015 Sep;59(9):5535-41
pubmed: 26124157
Ther Drug Monit. 2012 Aug;34(4):467-76
pubmed: 22722776
Eur J Clin Pharmacol. 2018 Aug;74(8):1091-1092
pubmed: 29705821
Antimicrob Agents Chemother. 2009 Feb;53(2):785-7
pubmed: 19047655
J Antimicrob Chemother. 1999 Aug;44(2):235-42
pubmed: 10473231
J Antimicrob Chemother. 2017 Aug 1;72(8):2342-2350
pubmed: 28575511
Ann Pharmacother. 2005 Jan;39(1):32-8
pubmed: 15598967
PLoS One. 2018 Jul 30;13(7):e0201667
pubmed: 30059536
Clin Microbiol Infect. 2015 Apr;21(4):337-43
pubmed: 25595706
Clin Microbiol Infect. 2013 May;19(5):474-9
pubmed: 22524597
Int J Antimicrob Agents. 2006 Oct;28(4):333-9
pubmed: 16942864
Ann Intern Med. 2009 May 5;150(9):604-12
pubmed: 19414839
J Antimicrob Chemother. 2016 Jan;71(1):196-207
pubmed: 26433783
Antimicrob Agents Chemother. 2012 Apr;56(4):2129-31
pubmed: 22290984
J Antimicrob Chemother. 2020 Oct 1;75(10):3029-3037
pubmed: 32681168